AMYLOIDOSIS RESEARCH CONSORTIUM INC
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$4,674,963
Investments
60%
Cash & Equivalents
37%
Receivables (Non-Related)
3%
Prepaid Expenses
<1%
Property, Plant, & Equipment (net)
<1%
Related-Party Receivables
0%
Inventories
0%
Other Assets
0%
Liabilities in 2024 (Year End)
$1,590,167
Deferred Revenue
87%
Payables & Accruals
13%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Other Liabilities
0%
Assets
2023
2024
Change
Cash & Equivalents
$834,738
$1,724,466
+107%
Receivables (Non-Related)
$64,903
$139,163
+114%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$24,958
$24,294
-3%
Investments
$2,041,743
$2,783,873
+36%
Property, Plant, & Equipment (net)
$8,924
$3,167
-65%
Other Assets
-
-
-
Total Assets
$2,975,266
$4,674,963
+57%
Liabilities
2023
2024
Change
Payables & Accruals
$226,503
$214,384
-5%
Grants Payable
-
-
-
Deferred Revenue
-
$1,375,783
-
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
-
-
-
Total Liabilities
$226,503
$1,590,167
+602%
Net assets
2023
2024
Change
Restricted Net Assets
$822,952
$692,879
-16%
Unrestricted Net Assets
$1,925,811
$2,391,917
+24%
Net assets
2023
2024
Change
Net assets
+$2,748,763
+$3,084,796
+12%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)